Regulus Therapeutics Inc (NASDAQ:RGLS) shares traded -1.32% lower at $1.49 on Wall Street last session.
RGLS stock price is now -3.07% away from the 50-day moving average and -19.36% away from the 200-day moving average. The market capitalization of the company currently stands at $97.60M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $7, Oppenheimer recently initiated with Outperform rating for Regulus Therapeutics Inc (NASDAQ: RGLS). On March 18, 2024, Leerink Partners recently initiated its ‘Outperform’ rating on the stock quoting a target price of $6, while ‘B. Riley FBR Inc.’ rates the stock as ‘Neutral’
In other news, Collier Kathryn J, Director bought 4,000 shares of the company’s stock on Jul 25 ’24. The stock was bought for $7,280 at an average price of $1.82. Upon completion of the transaction, the Director now directly owns 6,740 shares in the company, valued at $10042.6. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 18 ’24, Chief Financial Officer CALSADA CRISPINA sold 5,468 shares of the business’s stock. A total of $6,510 was realized by selling the stock at an average price of $1.19. This leaves the insider owning 5,782 shares of the company worth $8615.18. A total of 19.20% of the company’s stock is owned by insiders.
During the past 12 months, Regulus Therapeutics Inc has had a low of $1.08 and a high of $3.79. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 13.65, and a quick ratio of 13.65. The fifty day moving average price for RGLS is $1.5362 and a two-hundred day moving average price translates $1.8538 for the stock.
The latest earnings results from Regulus Therapeutics Inc (NASDAQ: RGLS) was released for 2024-09-30. The company reported revenue of $15.21 million for the quarter, compared to $8.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 87.2 percent.
